Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study.
Clinical lymphoma, myeloma & leukemia.
Times cited: 26
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Times cited: 76
A phase II trial of CI-921 in advanced malignancies.
Investigational new drugs.
Times cited: 23